CA1183452A - Rabies vaccine - Google Patents
Rabies vaccineInfo
- Publication number
- CA1183452A CA1183452A CA000371357A CA371357A CA1183452A CA 1183452 A CA1183452 A CA 1183452A CA 000371357 A CA000371357 A CA 000371357A CA 371357 A CA371357 A CA 371357A CA 1183452 A CA1183452 A CA 1183452A
- Authority
- CA
- Canada
- Prior art keywords
- rabies
- virus
- inactivated
- vaccine
- neg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960003127 rabies vaccine Drugs 0.000 title claims abstract description 28
- 241000711798 Rabies lyssavirus Species 0.000 claims abstract description 31
- 241000282324 Felis Species 0.000 claims abstract description 11
- 241000282465 Canis Species 0.000 claims abstract description 10
- 241000700605 Viruses Species 0.000 claims description 54
- 206010037742 Rabies Diseases 0.000 claims description 45
- 210000001550 testis Anatomy 0.000 claims description 23
- 241000282898 Sus scrofa Species 0.000 claims description 21
- 238000004113 cell culture Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 9
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims description 6
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical group O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 5
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 5
- 230000036039 immunity Effects 0.000 claims description 5
- 229960000380 propiolactone Drugs 0.000 claims description 5
- 230000000415 inactivating effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940124861 Rabies virus vaccine Drugs 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 7
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 1
- 230000001902 propagating effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 33
- 238000002360 preparation method Methods 0.000 abstract description 6
- 238000002649 immunization Methods 0.000 abstract description 2
- 230000003053 immunization Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 25
- 238000002255 vaccination Methods 0.000 description 20
- 241000282472 Canis lupus familiaris Species 0.000 description 18
- 241000282326 Felis catus Species 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 14
- 239000012530 fluid Substances 0.000 description 10
- 210000003292 kidney cell Anatomy 0.000 description 10
- 241000218642 Abies Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 5
- 229940031348 multivalent vaccine Drugs 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000699800 Cricetinae Species 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 239000013553 cell monolayer Substances 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000000655 Distemper Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010051497 Rhinotracheitis Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 101100316907 African swine fever virus (isolate Tick/Malawi/Lil 20-1/1983) Mal-144 gene Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000701114 Canine adenovirus 2 Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000009305 pseudorabies Diseases 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- VMXUWOKSQNHOCA-UKTHLTGXSA-N ranitidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-UKTHLTGXSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012770 revaccination Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/818—Viral vaccine for canidae or mustelidae, e.g. dogs, foxes, minks
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/819—Viral vaccine for feline species, e.g. cats
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000462315A CA1198368A (en) | 1980-07-30 | 1984-08-31 | Rabies vaccine |
| CA000475507A CA1205380A (en) | 1980-07-30 | 1985-02-28 | Rabies vaccine |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/174,306 US4347239A (en) | 1980-07-30 | 1980-07-30 | Inactivated rabies vaccine for veterinary use |
| US174,306 | 1980-07-30 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000462315A Division CA1198368A (en) | 1980-07-30 | 1984-08-31 | Rabies vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1183452A true CA1183452A (en) | 1985-03-05 |
Family
ID=22635689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000371357A Expired CA1183452A (en) | 1980-07-30 | 1981-02-20 | Rabies vaccine |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4347239A (en, 2012) |
| EP (1) | EP0044920B1 (en, 2012) |
| JP (1) | JPS5732227A (en, 2012) |
| KR (1) | KR840001514B1 (en, 2012) |
| AU (1) | AU544338B2 (en, 2012) |
| CA (1) | CA1183452A (en, 2012) |
| DE (1) | DE3160560D1 (en, 2012) |
| ES (1) | ES500199A0 (en, 2012) |
| HK (1) | HK50184A (en, 2012) |
| IE (1) | IE50889B1 (en, 2012) |
| NZ (1) | NZ196214A (en, 2012) |
| PH (3) | PH17383A (en, 2012) |
| SG (1) | SG3384G (en, 2012) |
| ZA (1) | ZA811042B (en, 2012) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4664912A (en) * | 1984-10-01 | 1987-05-12 | Wiktor Tadeusz J | Process for the large scale production of rabies vaccine |
| DE3526809A1 (de) * | 1985-07-26 | 1987-04-02 | Behringwerke Ag | Tollwut-lebendimpfstoff |
| DE3682482D1 (de) * | 1985-11-22 | 1991-12-19 | Schweiz Serum & Impfinst | Verfahren zur herstellung eines tollwutimpfstoffes und nach diesem verfahren erhaltener impfstoff. |
| US4990367A (en) * | 1987-03-09 | 1991-02-05 | Diamond Scientific Company | Canine distemper virus vaccine |
| RU2134590C1 (ru) * | 1997-11-24 | 1999-08-20 | Всероссийский научно-исследовательский институт защиты животных | Способ изготовления инактивированной вакцины против бешенства животных |
| RU2191600C1 (ru) * | 2001-12-20 | 2002-10-27 | Скичко Николай Данилович | Способ получения антирабической вакцины |
| RU2287343C1 (ru) * | 2005-05-31 | 2006-11-20 | ОАО "Институт биотехнологий ветеринарной медицины" | Способ получения антирабической вакцины |
| US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| RU2366457C1 (ru) * | 2008-02-27 | 2009-09-10 | Государственное научное учреждение Всероссийский научно-исследовательский и технологический институт биологической промышленности РАСХН | Вакцина антирабическая для животных (унирэв) |
| CN101846683B (zh) * | 2010-06-22 | 2014-08-06 | 普莱柯生物工程股份有限公司 | 一种猪瘟活疫苗效力检验方法 |
| RU2537183C2 (ru) * | 2012-12-17 | 2014-12-27 | Открытое Акционерное Общество "Институт Биотехнологий Ветеринарной Медицины" | Способ получения инактивированной антирабической вакцины при безопорном выращивании клеток и репродукции в них вируса в укороченном цикле культивирования |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1030516B (de) * | 1957-03-14 | 1958-05-22 | Dr Med Gustav Seiffert | Naehrboden zur Viruszuechtung |
| US3155589A (en) * | 1958-04-14 | 1964-11-03 | Upjohn Co | Parenteral extravascular injectable vaccines for simultaneous immunization of canidae against rabies, canine distemper, and infectious canine hepatitis |
| US3397267A (en) * | 1964-09-21 | 1968-08-13 | Research Corp | Method of producing rabies vaccine |
| US3423505A (en) * | 1964-10-31 | 1969-01-21 | Univ Toronto | Rabies vaccine and process for preparation thereof |
| US3585266A (en) * | 1969-02-24 | 1971-06-15 | Dow Chemical Co | Live rabies virus vaccine and method for the production thereof |
| US3769415A (en) * | 1969-06-04 | 1973-10-30 | Connaught Labor Ltd | Method of preparing a killed vaccine for oral use |
| DE2162013C3 (de) | 1971-12-14 | 1981-10-15 | Johnson & Johnson, 08903 New Brunswick, N.J. | Tollwut-Lebendimpfstoff, Verfahren zu seiner Herstellung nd seine Verwendung bei der Bekämpfung von Tollwut |
| FR2261779A1 (en) | 1974-02-26 | 1975-09-19 | Pasteur Institut | Anti-rabies vaccine - obtd. from rabies virus grown on foetal calf kidney cells in a synthetic serum-free medium |
| FR2290220A2 (fr) | 1974-11-05 | 1976-06-04 | Pasteur Institut | Nouveau vaccin antirabique |
| US4040904A (en) * | 1975-07-21 | 1977-08-09 | Slater Eban A | Novel rabies virus vaccine and processes |
| DE2616407C3 (de) * | 1976-04-14 | 1980-02-21 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Tollwut-Impfstoffs |
| US4070453A (en) * | 1976-06-25 | 1978-01-24 | Syntex (U.S.A.) Inc. | Diploid porcine embryonic cell strains, cultures produced therefrom, and use of said cultures for production of vaccines |
| GB1596653A (en) | 1977-01-26 | 1981-08-26 | Gist Brocades Nv | Vaccine |
| BE859178A (fr) | 1977-09-29 | 1978-01-16 | Cutter Lab | Souche de cellules et culture de virus |
-
1980
- 1980-07-30 US US06/174,306 patent/US4347239A/en not_active Expired - Lifetime
-
1981
- 1981-02-09 IE IE240/81A patent/IE50889B1/en not_active IP Right Cessation
- 1981-02-09 NZ NZ196214A patent/NZ196214A/en unknown
- 1981-02-10 AU AU67143/81A patent/AU544338B2/en not_active Expired
- 1981-02-13 PH PH25224A patent/PH17383A/en unknown
- 1981-02-17 ZA ZA00811042A patent/ZA811042B/xx unknown
- 1981-02-19 JP JP2416581A patent/JPS5732227A/ja active Granted
- 1981-02-20 CA CA000371357A patent/CA1183452A/en not_active Expired
- 1981-03-09 ES ES500199A patent/ES500199A0/es active Granted
- 1981-06-04 EP EP81104298A patent/EP0044920B1/en not_active Expired
- 1981-06-04 DE DE8181104298T patent/DE3160560D1/de not_active Expired
- 1981-06-30 KR KR1019810002356A patent/KR840001514B1/ko not_active Expired
-
1983
- 1983-08-19 PH PH29417A patent/PH18743A/en unknown
-
1984
- 1984-01-13 SG SG33/84A patent/SG3384G/en unknown
- 1984-06-21 HK HK501/84A patent/HK50184A/en not_active IP Right Cessation
-
1985
- 1985-01-18 PH PH31737A patent/PH22308A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU544338B2 (en) | 1985-05-23 |
| ES8202357A1 (es) | 1982-01-16 |
| HK50184A (en) | 1984-06-29 |
| SG3384G (en) | 1985-02-01 |
| KR830005871A (ko) | 1983-09-14 |
| EP0044920B1 (en) | 1983-07-06 |
| NZ196214A (en) | 1984-07-31 |
| KR840001514B1 (ko) | 1984-09-29 |
| EP0044920A3 (en) | 1982-02-17 |
| AU6714381A (en) | 1982-02-04 |
| IE50889B1 (en) | 1986-08-06 |
| PH22308A (en) | 1988-07-22 |
| EP0044920A2 (en) | 1982-02-03 |
| PH18743A (en) | 1985-09-16 |
| ZA811042B (en) | 1982-05-26 |
| ES500199A0 (es) | 1982-01-16 |
| JPS5732227A (en) | 1982-02-20 |
| IE810240L (en) | 1982-01-30 |
| JPH0555487B2 (en, 2012) | 1993-08-17 |
| US4347239A (en) | 1982-08-31 |
| PH17383A (en) | 1984-08-06 |
| DE3160560D1 (en) | 1983-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0145783B2 (en) | Canine coronavirus vaccine | |
| US7879336B2 (en) | Vaccines and methods to treat canine influenza | |
| EP0189958B1 (en) | Canine parvovirus vaccines | |
| US4904468A (en) | Canine coronavirus vaccine | |
| CA1183452A (en) | Rabies vaccine | |
| US4429045A (en) | Rabies virus adapted for growth in swine testicle cell culture | |
| US3925544A (en) | Bovine vaccines and methods of making and using same | |
| US4584194A (en) | Inactivated rabies vaccine for veterinary use | |
| Russell et al. | Characterization of infectious laryngotracheitis viruses, antigenic comparison by kinetics of neutralization and immunization studies | |
| US4726946A (en) | Inactivated rabies vaccine for veterinary use | |
| US4711778A (en) | Inactivated rabies vaccine for veterinary use | |
| CA1205380A (en) | Rabies vaccine | |
| CA1198368A (en) | Rabies vaccine | |
| Parker | Inactivation of African horse-sickness virus by betapropiolactone and by pH | |
| US3674862A (en) | Live attenuated rabies virus vaccine and process therefor | |
| Shibley et al. | United States Department of Agriculture licensing requirements for feline leukemia virus vaccines | |
| Rangga-Tabbu et al. | Marek's disease virus (MDV) antigens in the feather follicle epithelium: difference between oncogenic and nononcogenic MDV | |
| Coria et al. | Immune response in chickens to infectious bronchitis virus, strain 33 I. Response to beta-propiolactone-inactivated virus | |
| US7041299B2 (en) | Escape mutants of newcastle disease virus as marker vaccines | |
| Westbury | Serological response of chickens, turkeys and ducks to strain V4 of Newcastle disease virus | |
| Zhang et al. | Evaluation of immune response and protection in animals given mink parvovirus vaccines | |
| El-Bagoury et al. | Improving performance of Pneumo-4 vaccine using montanide oil | |
| Agrawal | The evaluation of using vegetable oils as adjuvants with Newcastle disease virus vaccine when administered by a non-injectable route | |
| Cook | Development of a gene deleted pseudorabies (Aujeszky's disease) vaccine and evaluation of a differential diagnostic serology test | |
| Philips | Veterinary Biological Products of Viral Origin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |